Patrick Donnelly
Stock Analyst at Citigroup
(3.44)
# 915
Out of 5,163 analysts
374
Total ratings
46.77%
Success rate
4.2%
Average return
Main Sectors:
Stocks Rated by Patrick Donnelly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDLN Medline | Reinstates: Buy | $60 | $41.46 | +44.72% | 3 | Mar 11, 2026 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $200 → $120 | $98.33 | +22.04% | 11 | Mar 11, 2026 | |
| STVN Stevanato Group | Maintains: Buy | $32 → $26 | $14.99 | +73.45% | 5 | Mar 5, 2026 | |
| SHC Sotera Health Company | Maintains: Buy | $21 → $23 | $13.42 | +71.45% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Buy | $135 → $150 | $85.49 | +75.46% | 12 | Feb 20, 2026 | |
| BRKR Bruker | Maintains: Neutral | $53 → $40 | $33.75 | +18.52% | 19 | Feb 13, 2026 | |
| QDEL QuidelOrtho | Maintains: Neutral | $23 → $30 | $17.10 | +75.44% | 7 | Feb 12, 2026 | |
| AVTR Avantor | Maintains: Neutral | $13 → $11 | $7.93 | +38.71% | 9 | Feb 12, 2026 | |
| DGX Quest Diagnostics | Maintains: Neutral | $190 → $215 | $199.70 | +7.66% | 12 | Feb 10, 2026 | |
| QGEN Qiagen | Maintains: Neutral | $55 → $55 | $40.60 | +35.47% | 15 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $230 → $200 | $164.72 | +21.42% | 14 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $80 | $50.85 | +57.33% | 13 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $685 | $464.37 | +47.51% | 22 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $265 | $155.46 | +70.46% | 22 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $300 | $187.85 | +59.70% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 | $18.79 | -4.20% | 13 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $21 | $8.94 | +134.90% | 5 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $185 | $111.51 | +65.90% | 27 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,600 → $1,700 | $1,173.74 | +44.84% | 15 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $375 | $262.80 | +42.69% | 17 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $375 | $264.40 | +41.83% | 17 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $42 | $18.15 | +131.40% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $60 → $80 | $75.12 | +6.50% | 15 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $85 → $80 | $118.94 | -32.74% | 17 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $265 | $187.32 | +41.47% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $75 | $103.57 | -27.59% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $145 | $85.57 | +69.45% | 1 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $265 → $300 | $286.57 | +4.69% | 24 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $2.97 | +203.03% | 6 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.75 → $2.75 | $2.13 | +29.41% | 4 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $250 → $260 | $263.80 | -1.44% | 11 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $6.72 | -10.71% | 4 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $28 → $32 | $4.66 | +586.70% | 2 | Nov 30, 2018 |
Medline
Mar 11, 2026
Reinstates: Buy
Price Target: $60
Current: $41.46
Upside: +44.72%
ICON Public Limited Company
Mar 11, 2026
Maintains: Neutral
Price Target: $200 → $120
Current: $98.33
Upside: +22.04%
Stevanato Group
Mar 5, 2026
Maintains: Buy
Price Target: $32 → $26
Current: $14.99
Upside: +73.45%
Sotera Health Company
Feb 24, 2026
Maintains: Buy
Price Target: $21 → $23
Current: $13.42
Upside: +71.45%
Guardant Health
Feb 20, 2026
Maintains: Buy
Price Target: $135 → $150
Current: $85.49
Upside: +75.46%
Bruker
Feb 13, 2026
Maintains: Neutral
Price Target: $53 → $40
Current: $33.75
Upside: +18.52%
QuidelOrtho
Feb 12, 2026
Maintains: Neutral
Price Target: $23 → $30
Current: $17.10
Upside: +75.44%
Avantor
Feb 12, 2026
Maintains: Neutral
Price Target: $13 → $11
Current: $7.93
Upside: +38.71%
Quest Diagnostics
Feb 10, 2026
Maintains: Neutral
Price Target: $190 → $215
Current: $199.70
Upside: +7.66%
Qiagen
Feb 6, 2026
Maintains: Neutral
Price Target: $55 → $55
Current: $40.60
Upside: +35.47%
Feb 6, 2026
Maintains: Neutral
Price Target: $230 → $200
Current: $164.72
Upside: +21.42%
Feb 5, 2026
Maintains: Buy
Price Target: $70 → $80
Current: $50.85
Upside: +57.33%
Jan 30, 2026
Maintains: Buy
Price Target: $660 → $685
Current: $464.37
Upside: +47.51%
Jan 16, 2026
Maintains: Buy
Price Target: $200 → $265
Current: $155.46
Upside: +70.46%
Jan 7, 2026
Initiates: Buy
Price Target: $300
Current: $187.85
Upside: +59.70%
Dec 11, 2025
Downgrades: Neutral
Price Target: $18
Current: $18.79
Upside: -4.20%
Dec 11, 2025
Upgrades: Buy
Price Target: $12 → $21
Current: $8.94
Upside: +134.90%
Nov 25, 2025
Maintains: Buy
Price Target: $165 → $185
Current: $111.51
Upside: +65.90%
Nov 10, 2025
Maintains: Buy
Price Target: $1,600 → $1,700
Current: $1,173.74
Upside: +44.84%
Oct 30, 2025
Maintains: Buy
Price Target: $350 → $375
Current: $262.80
Upside: +42.69%
Oct 30, 2025
Maintains: Buy
Price Target: $350 → $375
Current: $264.40
Upside: +41.83%
Aug 13, 2025
Maintains: Buy
Price Target: $34 → $42
Current: $18.15
Upside: +131.40%
Jul 9, 2025
Upgrades: Buy
Price Target: $60 → $80
Current: $75.12
Upside: +6.50%
Jul 9, 2025
Downgrades: Sell
Price Target: $85 → $80
Current: $118.94
Upside: -32.74%
Jan 30, 2025
Maintains: Buy
Price Target: $285 → $265
Current: $187.32
Upside: +41.47%
Nov 6, 2024
Maintains: Buy
Price Target: $80 → $75
Current: $103.57
Upside: -27.59%
Jul 30, 2024
Maintains: Buy
Price Target: $135 → $145
Current: $85.57
Upside: +69.45%
Dec 11, 2023
Maintains: Neutral
Price Target: $265 → $300
Current: $286.57
Upside: +4.69%
Dec 11, 2023
Maintains: Buy
Price Target: $7 → $9
Current: $2.97
Upside: +203.03%
Aug 10, 2023
Maintains: Neutral
Price Target: $3.75 → $2.75
Current: $2.13
Upside: +29.41%
Feb 17, 2023
Maintains: Neutral
Price Target: $250 → $260
Current: $263.80
Upside: -1.44%
Nov 3, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $6.72
Upside: -10.71%
Nov 30, 2018
Upgrades: Neutral
Price Target: $28 → $32
Current: $4.66
Upside: +586.70%